Allergan plc (AGN) Holdings Decreased by Gillespie Robinson & Grimm Inc.
Gillespie Robinson & Grimm Inc. reduced its position in Allergan plc (NYSE:AGN) by 53.8% in the fourth quarter, HoldingsChannel.com reports. The firm owned 50,797 shares of the company’s stock after selling 59,094 shares during the period. Gillespie Robinson & Grimm Inc.’s holdings in Allergan were worth $8,309,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently bought and sold shares of AGN. Beach Investment Management LLC. boosted its position in shares of Allergan by 845.2% in the second quarter. Beach Investment Management LLC. now owns 93,195 shares of the company’s stock worth $22,655,000 after purchasing an additional 83,335 shares during the period. Peddock Capital Advisors LLC bought a new position in shares of Allergan in the second quarter worth approximately $1,718,000. iAB Financial Bank boosted its position in shares of Allergan by 77.3% in the second quarter. iAB Financial Bank now owns 1,775 shares of the company’s stock worth $431,000 after purchasing an additional 774 shares during the period. Graybill Bartz & Assoc Ltd. boosted its position in shares of Allergan by 1.4% in the second quarter. Graybill Bartz & Assoc Ltd. now owns 17,886 shares of the company’s stock worth $4,348,000 after purchasing an additional 251 shares during the period. Finally, Boston Private Wealth LLC boosted its position in shares of Allergan by 7.3% in the second quarter. Boston Private Wealth LLC now owns 92,663 shares of the company’s stock worth $22,525,000 after purchasing an additional 6,344 shares during the period. Institutional investors and hedge funds own 81.14% of the company’s stock.
A number of equities analysts have weighed in on AGN shares. Cowen reiterated a “buy” rating on shares of Allergan in a research report on Thursday, October 12th. Wells Fargo & Co reissued a “buy” rating on shares of Allergan in a report on Monday, October 2nd. Mizuho reissued a “buy” rating and issued a $267.00 target price on shares of Allergan in a report on Monday, September 25th. UBS Group reissued a “buy” rating and issued a $275.00 target price on shares of Allergan in a report on Tuesday, September 26th. Finally, Deutsche Bank reissued a “buy” rating and issued a $262.00 target price on shares of Allergan in a report on Tuesday, September 12th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $227.22.
Allergan plc (AGN) traded down $3.09 during trading on Wednesday, reaching $172.56. 937,185 shares of the company were exchanged, compared to its average volume of 3,020,000. The stock has a market capitalization of $58,420.00, a P/E ratio of -7.64, a price-to-earnings-growth ratio of 1.18 and a beta of 1.11. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.40. Allergan plc has a 52 week low of $160.07 and a 52 week high of $256.80.
Allergan (NYSE:AGN) last released its quarterly earnings results on Wednesday, November 1st. The company reported $4.15 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.06 by $0.09. The company had revenue of $4.03 billion for the quarter, compared to the consensus estimate of $4.04 billion. Allergan had a negative net margin of 47.27% and a positive return on equity of 8.00%. Allergan’s revenue was up 11.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.32 earnings per share. sell-side analysts anticipate that Allergan plc will post 16.27 EPS for the current year.
The firm also recently declared a quarterly dividend, which was paid on Friday, December 15th. Investors of record on Friday, November 17th were paid a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a yield of 1.62%. The ex-dividend date was Thursday, November 16th. Allergan’s payout ratio is -12.39%.
Allergan announced that its board has initiated a share buyback plan on Monday, September 25th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the company to reacquire up to 2.8% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s leadership believes its shares are undervalued.
In related news, insider William Meury sold 11,807 shares of the company’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $173.89, for a total transaction of $2,053,119.23. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Chris W. Bodine purchased 3,030 shares of the firm’s stock in a transaction that occurred on Thursday, December 7th. The shares were acquired at an average cost of $164.77 per share, for a total transaction of $499,253.10. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 17,630 shares of company stock worth $2,890,057. 0.36% of the stock is owned by insiders.
ILLEGAL ACTIVITY NOTICE: “Allergan plc (AGN) Holdings Decreased by Gillespie Robinson & Grimm Inc.” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/allergan-plc-agn-holdings-decreased-by-gillespie-robinson-grimm-inc/1801374.html.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with Analyst Ratings Network's FREE daily email newsletter.